Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor

  • GH-R feedback on pituitaries.pdf 

    download

None
Share this:
Embed*
Cite this:

Diaz-Cano, Salvador J.; Grossman, A B; Kola, B; Korbonits, M; Powell, M; Arnaldi, G; Kaltsas, G; Czirjak, S; Metherell, L; Morris, D G; Boscaro, M; Bustin, S; Mantero, F; Jordan, S (2012): Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor. figshare.

http://dx.doi.org/10.6084/m9.figshare.97555
Retrieved 00:21, Oct 02, 2014 (GMT)

Description

Clinical acromegaly is characterized by elevated GH secretion in the presence of high circulating IGF-I levels. We hypothesized that the physiological IGF-I/GH negative feedback loop may be reset in somatotroph adenomas, specifically in terms of the level of expression of these receptors or mutations of the GH receptor (GH-R) in such tumours.
We therefore investigated the full coding sequence of the GH-R in a series of somatotroph and other pituitary adenomas. We also investigated the mRNA expression of these putative feedback receptors in a series of pituitary adenomas and normal pituitary tissue, and their protein expression by immunostaining. Real-time RT-PCR assay was used for the quantification of the type 1 IGF receptor (IGF-R) and GH receptor (GH-R) mRNA, and sequence analysis was performed on the coding region of the GH-R gene.
No somatic mutations of the GH-R mRNA were detected in 18 GH-secreting tumours or two nonfunctioning pituitary adenomas (NFPAs). However, the levels of GH-R mRNA were significantly lower in both somatotroph tumours and NFPAs compared to the normal pituitary (P < 0.05 for both). Immunostaining for GH-R also showed significantly less GH-R expression in somatotroph adenomas compared to normal pituitary tissue (P < 0.0001). IGF-R mRNA levels were significantly lower in somatotroph tumours compared to normal pituitary (P = 0.005), and trended lower in corticotroph tumours (P = 0.07), while the other tumour types showed no significant difference from normal pituitary. Immunostaining for IGF-R also showed less IGF-R protein in the somatotroph adenomas compared to the normal pituitary tissue (P < 0.01).
Our findings suggest that decreased feedback inhibition of GH because of somatic mutations of the coding region of the GH-R are unlikely to be a common factor in the pathogenesis of these tumours. Nevertheless, decreased expression of the GH-R and of IGF-R in somatotroph tumours (both at the mRNA and protein level) may, at least in part, help explain the continuous secretion of GH from the tumour despite the high circulating levels of IGF-I and GH.

Links

Comments (0)

You must be logged in to post comments.

29
views

0
shares

Published on 15 Nov 2012 - 14:06 (GMT)

Filesize is 293.53 KB

Categories

Authors

  • Salvador J. Diaz-Cano
  • A B Grossman
  • B Kola
  • M Korbonits
  • M Powell
  • G Arnaldi
  • G Kaltsas
  • S Czirjak
  • L Metherell
  • D G Morris
  • M Boscaro
  • S Bustin
  • F Mantero
  • S Jordan

Tags

License (what's this?)

CC-BY

Export

Cite "Filename"

Place your mouse over the citation text to select it

Embed "Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor"

Place your mouse over the embed code to select and copy it

Claim article

You claim request was sent. I will be handled in the next 24 hours.

Close window

Feedback

We appreciate all your comments, questions, suggestions or gratitude.

Login

The username or password entered are wrong.

Reset password

Your password will be sent to your registered e-mail address.

Create account

I agree to the Terms & Conditions *